United States: Consulting Agreement Did Not Assign Patent Rights From Pre-Agreement Contributions

Abstract

The Federal Circuit recently analyzed whether a consulting agreement provided for an assignment of the consultant's patent rights stemming from his contributions prior to the agreement's effective date. The agreement required the consultant to list all of his prior inventions and provided that the failure to list any such prior inventions constituted a representation that none existed. The company argued that certain work performed by the consultant prior to the effective date and not listed in the agreement was assigned to the company. Disagreeing, the Federal Circuit found that nothing in the agreement suggested the consultant's prior inventions would be assigned to the company, and that the representation of no prior inventions failed to prevent the consultant from licensing such inventions to competitors of the company that engaged the consultant. As a result, when the company sued a competitor for patent infringement, the competitor obtained a license from the consultant on the prior relevant invention of the consultant and relied on that license as a defense to the patent infringement suit by the manufacturer. The case, however, was remanded to the district court to determine whether the consultant's prior work continued after the effective date such that rights in the work would be assigned to the company.

Companies frequently contract with outside consultants to assist with product development. Because collaboration with consultants may lead to patent-eligible discoveries, however, it is important that consulting agreements define the rights between the parties in any patented inventions that arise out of their work. Recently, in TriReme Medical, LLC v. AngioScore, Inc.1, the Federal Circuit analyzed whether a consulting agreement provided for an assignment of the consultant's patent rights stemming from his contributions prior to the agreement's effective date. The Federal Circuit found that nothing in the agreement suggested that the consultant's rights in work prior to the effective date would be assigned to the hiring company. The case, however, was remanded to the district court to determine whether the consultant's prior work in question continued after the effective date such that the company owned any rights in those works.

Background

AngioScore owns patents directed to angioplasty balloon catheters used to open arterial blockages. AngioScore's commercial product AngioSculpt was developed with the assistance of Dr. Chaim Lotan, who served as a consultant for AngioScore. Before the effective date of the Consulting Agreement, Dr. Lotan performed work relating to AngioScore's patents. According to Dr. Lotan, during meetings with AngioScore he made a recommendation to improve AngioScore's product, which later became a part of AngioScore's patented invention.

TriReme Medical, a competitor of AngioScore, sought to acquire an interest in the AngioScore patents from Dr. Lotan. Despite not being named as an inventor on the patents, Dr. Lotan granted TriReme an exclusive license to "any and all legal and equitable rights" he held in the AngioScore patents. Under this license, if Dr. Lotan was an inventor of the AngioScore patents, TriReme would have a defense to infringement that would allow it to freely practice the patented inventions.

Seeking to have Dr. Lotan named as an inventor, TriReme brought suit in the Northern District of California for correction of inventorship of the AngioScore patents. AngioScore moved to dismiss the action, arguing that under the Consulting Agreement between Dr. Lotan and AngioScore, Dr. Lotan had already assigned to AngioScore any rights he may have had stemming from his contribution to the patents, and he thus had nothing to later license to TriReme.

Two provisions of the Consulting Agreement were at issue:

9. Inventions
(a) Inventions Retained and Licensed. Consultant has attached hereto, as part of Exhibit C, a list describing all inventions, original works of authorship, developments, improvements, and trade secrets which were made by Consultant prior to the date of this Agreement (collectively referred to as "Prior Inventions"), that belong solely to Consultant or belong to Consultant jointly with another and that relate to any of the Company's current or proposed businesses, products or research and development; or if no such list is attached, Consultant represents that there are no such Prior Inventions. If, in the course of providing the Services, Consultant incorporates into a Company product, process or machine or into any Invention (as defined below), a Prior Invention owned by Consultant or in which Consultant has an interest, the Company is hereby granted and shall have a non-exclusive license (with the right to sublicense) to make, have made, copy, modify, make derivative works of, use, sell and otherwise distribute such Prior Inventions as part of or in connection with such product, process, machine or Invention.

(b) Assignment of Inventions. Consultant agrees to promptly disclose to the Company and hereby assigns to the Company, or its designee, all right, title and interest in and to all inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets, whether or not patentable, that Consultant may solely or jointly conceive or develop or reduce to practice during the term of this Agreement that relate to the Services (collectively referred to as "Inventions").

Section 9(a) required Dr. Lotan to list all of his inventions made before the Agreement's effective date that related to AngioScore's business. AngioScore would receive a nonexclusive license to any prior invention Dr. Lotan incorporated into AngioScore's products during the course of his consulting work. Failure to list any such prior inventions constituted a representation that none existed.

Section 9(b) called for an assignment of Dr. Lotan's rights to AngioScore for any inventions conceived, developed, or reduced to practice during the term of the Agreement.

According to AngioScore, under either section 9(a) or 9(b), it acquired all of Dr. Lotan's rights in certain work performed prior to the Agreement's effective date and which Dr. Lotan failed to list as a prior invention under the Agreement. The district court agreed and dismissed TriReme's suit. TriReme appealed to the Federal Circuit.

The Federal Circuit's Decision

The Federal Circuit reversed the district court's decision. Turning to the express language of section 9(a), the Court found that nothing in the terms of section 9(a) suggested that Dr. Lotan would not retain ownership of any prior invention that he failed to list under the Agreement. At most, the Court stated, section 9(a) granted AngioScore a non-exclusive license in the event that Dr. Lotan incorporated a prior invention into an AngioScore product during the term of the Agreement.

The Federal Circuit also rejected AngioScore's contention that, under estoppel by contract, TriReme was bound to Dr. Lotan's implicit representation that he had no prior inventions that were relevant to the development of AngioScore's prototype. The Court found that estoppel by contract did not apply because neither Dr. Lotan nor his successor in interest, TriReme, were seeking to enforce any rights under the Consulting Agreement, and AngioScore cited no cases that applied estoppel by contract where the cause of action was not founded in the written contract itself.

Next, the Federal Circuit considered AngioScore's alternative argument that Dr. Lotan had assigned all rights from his previous work under § 9(b), which provided for an assignment to AngioScore of Dr. Lotan's work performed during the term of the Agreement. AngioScore's theory was that Dr. Lotan's work prior to the effective date continued during the term of the Agreement and qualified as conceiving, developing, or reducing to practice an invention such that it would fall within the scope of § 9(b). Because this question of fact had not been adequately developed at the district court level, the Federal Circuit remanded to the district court to consider whether Dr. Lotan's continued work after the effective date fell within the language of § 9(b).

Strategy and Conclusion

This case illustrates the issues that arise when a background rights exist as well as the importance of having a carefully drafted ownership agreement in place before collaborating with a consultant or independent party to protect patent rights and identify any preexisting intellectual property owned by the consultant prior to entering into an agreement. In the current case, while a representation of no prior relevant inventions and a non-exclusive license protected the company engaging the consultant from being sued by the consultant for patent infringement, it failed to prevent the consultant from being estopped from licensing a prior relevant invention to a competitor of the company that engaged the consultant and creating a license defense to the patent infringement suit by the company that engaged the consultant.

Footnotes

1 The TriReme Medical, LLC v. AngioScore, Inc. decision may be found at http://www.finnegan.com/files/upload/LES_Insights_Column/2016/TriremeMedicalvAngioscoreInc..pdf.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
23 Sep 2018, Seminar, Chicago, United States

Finnegan is a sponsor of the Intellectual Property Owners Association Annual Meeting, supporting the Women in IP Networking Brunch.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions